Viking Therapeutics total liabilities and share holders equity for the quarter ending September 30, 2024 was $0.938B, a 145.1% increase year-over-year.
Viking Therapeutics total liabilities and share holders equity for 2023 was $0.368B, a 118.65% increase from 2022.
Viking Therapeutics total liabilities and share holders equity for 2022 was $0.169B, a 20% decline from 2021.
Viking Therapeutics total liabilities and share holders equity for 2021 was $0.211B, a 17.87% decline from 2020.
Viking Therapeutics Total Liabilities and Share Holders Equity 2014-2024 | VKTX